A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.

Pathology-derived estimates of tumor-infiltrating lymphocytes (PaTILS) did not differ between the response groups or between pre- and post-pET ( Figure 2F ), but we observed highly significant differences in Ki67 staining between R and NR cases at baseline and post-pET ( Figure 2G ).

also in 132,142 other papers